Other formats:
BibTeX
LaTeX
RIS
@article{1807988,
author = {Hyza, M. and Silhan, P. and Ceskova, E. and Skront, T. and Kacirova, I. and Urinovska, R. and Grundmann, M.},
article_location = {New Zealand},
doi = {http://dx.doi.org/10.2147/NDT.S298050},
keywords = {therapeutic drug monitoring; antipsychotics; psychotic disorders; schizophrenia},
language = {eng},
issn = {1176-6328},
journal = {Neuropsychiatric Disease and Treatment},
title = {Plasma Levels of Long-Acting Injectable Antipsychotics in Outpatient Care: A Retrospective Analysis},
url = {https://www.dovepress.com/plasma-levels-of-long-acting-injectable-antipsychotics-in-outpatient-c-peer-reviewed-fulltext-article-NDT},
volume = {17},
year = {2021}
}
TY - JOUR
ID - 1807988
AU - Hyza, M. - Silhan, P. - Ceskova, E. - Skront, T. - Kacirova, I. - Urinovska, R. - Grundmann, M.
PY - 2021
TI - Plasma Levels of Long-Acting Injectable Antipsychotics in Outpatient Care: A Retrospective Analysis
JF - Neuropsychiatric Disease and Treatment
VL - 17
SP - 1069-1075
EP - 1069-1075
PB - Dove Medical Press
SN - 11766328
KW - therapeutic drug monitoring
KW - antipsychotics
KW - psychotic disorders
KW - schizophrenia
UR - https://www.dovepress.com/plasma-levels-of-long-acting-injectable-antipsychotics-in-outpatient-c-peer-reviewed-fulltext-article-NDT
N2 - Purpose: Antipsychotic efficacy in schizophrenia depends on its availability in the body. Although therapeutic outcomes remain still far from satisfactory, therapeutic drug monitoring not a common part of clinical practice during treatment with long-acting injectable antipsychotics (LAI AP). The real effectiveness of LAI AP is thus uncertain. Patients and Methods: We made a retrospective evaluation of plasma levels of LAI AP. Collection of blood samples was performed just before the drug application and one week later. Forty patients with a stabilized clinical condition and steady-state plasma levels were included. Results: In the observed cohort of patients, flupentixol decanoate (n = 23) was the most often used drug, followed by fluphenazine decanoate (n = 7), haloperidol decanoate (n = 5), paliperidone palmitate (n = 3), and risperidone microspheres (n = 2). Just 5 of 40 patients were treated with a monotherapy. In the period before the application, 60% of the patients did not reach the therapeutic reference range (TRR) and 20% of the patients had an undetectable plasma level. At the time of collection of the second blood samples performed after 7 days, 24% of the patients were under the TRR. Conclusion: We have found a surprisingly high incidence of plasma levels under the TRR patients treated with LAI AP. Notwithstanding individual variability in pharmacokinetics, seems that LAI AP may be underdosed in usual clinical practice.
ER -
HYZA, M., P. SILHAN, E. CESKOVA, T. SKRONT, I. KACIROVA, R. URINOVSKA and M. GRUNDMANN. Plasma Levels of Long-Acting Injectable Antipsychotics in Outpatient Care: A Retrospective Analysis. \textit{Neuropsychiatric Disease and Treatment}. New Zealand: Dove Medical Press, 2021, vol.~17, p.~1069-1075. ISSN~1176-6328. Available from: https://dx.doi.org/10.2147/NDT.S298050.
|
